Indaptus Therapeutics (INDP) Long-Term Deferred Tax (2022 - 2025)
Indaptus Therapeutics (INDP) posted quarterly Long-Term Deferred Tax of $60.7 million for Q4 2025, up 6.66% year-over-year from $56.9 million in Q4 2024, and up 6.66% quarter-over-quarter from $56.9 million in Q4 2024.
Indaptus Therapeutics (INDP) Long-Term Deferred Tax (2022 - 2025) Analysis & Trends
Indaptus Therapeutics' Long-Term Deferred Tax history runs 4 years deep, the most recent figure standing at $60.7 million for Q4 2025.
- In Q4 2025, Long-Term Deferred Tax rose 6.66% year-over-year to $60.7 million; the TTM figure through Dec 2025 stood at $60.7 million (up 6.66% YoY), while the FY2025 annual figure was $60.7 million, up 6.66% from the prior year.
- Long-Term Deferred Tax for Q4 2025 stood at $60.7 million, up from $56.9 million in the prior quarter.
- The five-year high for Long-Term Deferred Tax was $60.7 million in Q4 2025, with the low at $50.2 million in Q4 2022.
- The 4-year median for Long-Term Deferred Tax is $54.4 million (2023), against an average of $54.9 million.
- The sharpest annual moves came in 2023 and 2024: Long-Term Deferred Tax gained 3.19% in 2023, then grew 9.84% in 2024.
- Indaptus Therapeutics' Long-Term Deferred Tax stood at $50.2 million in 2022, then increased by 3.19% to $51.8 million in 2023, then climbed by 9.84% to $56.9 million in 2024, then increased by 6.66% to $60.7 million in 2025.
- Business Quant data shows INDP's Long-Term Deferred Tax at $60.7 million in Q4 2025, $56.9 million in Q4 2024, and $51.8 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Indaptus Therapeutics | 146.91 Mn | 135.35 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 60.74 Mn |
| Dec 31, 2024 | 56.95 Mn |
| Dec 31, 2023 | 51.85 Mn |
| Dec 31, 2022 | 50.24 Mn |